What's Happening?
Researchers at the University of Colorado Boulder, in collaboration with Stanford and Baylor universities, have identified an appetite-suppressing compound in python blood that could lead to new weight loss therapies. The compound, para-tyramine-O-sulfate
(pTOS), was found to significantly increase in pythons after they consume large meals. This discovery is part of a broader study into the metabolic capabilities of pythons, which can consume large prey and go months without eating while maintaining metabolic health. The research team found that pTOS acts on the hypothalamus, the brain's appetite center, promoting weight loss in mice without the side effects associated with current weight loss drugs. The study suggests that pTOS could be developed into a therapy that promotes satiety without causing nausea or muscle loss.
Why It's Important?
The discovery of pTOS as a potential weight loss therapy is significant because it offers a new approach to managing obesity, a major health issue in the U.S. Current weight loss drugs often have side effects that limit their use, but pTOS could provide a more effective and tolerable alternative. The research highlights the potential of nature-inspired biology to address human health challenges. If successful, therapies derived from pTOS could benefit millions of Americans struggling with obesity, reducing healthcare costs and improving quality of life. Additionally, the study opens new avenues for research into other metabolic conditions, such as age-related muscle loss, by exploring the unique biological processes of pythons.
What's Next?
The research team plans to further investigate how pTOS functions in humans and explore other metabolites that increase in pythons after eating. They aim to develop chemically synthesized analogs of these metabolites for therapeutic use. The researchers have formed a start-up, Arkana Therapeutics, to commercialize their findings. Future studies will focus on understanding the broader implications of pTOS and other metabolites in human metabolism, potentially leading to new treatments for obesity and related conditions. The team is also interested in exploring the role of these compounds in preventing age-related muscle loss, a condition with no current therapies.
